We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
DXCM benefits from expanding CGM demand, with rising adoption of G7 and ONE across U.S. markets.
DXCM posted double-digit Q4 revenue growth, driven by Type 2 adoption and reimbursement gains.
DXCM faces rising competition, but Stelo traction and expanding coverage help drive adoption.
DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. However, risks related to stiff competition persist.
This Zacks Rank #3 (Hold) company’s shares have lost 17.7% in the past six months against the industry’s 10.6% growth. The S&P 500 Index has gained 13.1% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $27.18 billion. It projects a 22.5% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, the average surprise being 0.17%.
Let’s delve deeper.
CGM Market Represents a Huge Potential: The diabetes market offers massive long-term growth potential, with over 130 million people in the United States living with diabetes or prediabetes and more than 400 million affected globally, a figure expected to rise. This expanding patient base is driving strong demand for CGM devices, which help reduce hospitalizations, complications and overall treatment costs through real-time, user-friendly glucose tracking.
CGMs also enable more personalized diabetes management by allowing clinicians to tailor treatment plans based on individual data, while growing awareness and diagnosis of prediabetes further expand the addressable market. With the global CGM market projected to witness a 10% CAGR from over $6 billion today to about $14 billion by 2032, DexCom, as a leading CGM provider, is well positioned to deliver sustained growth over the next decade, driven by rising adoption and deeper market penetration.
Product Ecosystem and Innovation Driving Adoption: DexCom generates nearly 90% of its revenues from disposable CGM sensors, supported by strong demand driven by product performance and a positive user experience.The uptake of the G7 and One+ continues to accelerate, driven by broader insurance coverage, international expansion and growing physician support, especially among Type 2 diabetes patients.
Benefits like continuous readings without finger-pricking, comfortable wearability, and integrated alerts make DexCom’s systems compelling versus traditional glucose meters. The devices also connect to automated insulin delivery systems, which are becoming a key differentiator as diabetes care shifts toward smarter, closed-loop management.
Beyond hardware, DexCom’s software ecosystem is emerging as a powerful growth catalyst. New features, such as historical data review, AI-powered insights and deeper integration with platforms like Oura are helping patients better understand glucose trends and improve health-related decisions. This increases engagement and strengthens the company’s reimbursement case.
Stelo, launched in 2024, has already surpassed $100 million in its first year across Type 2, prediabetes and wellness markets, supported by strong subscription renewals and upcoming Amazon distribution. Together, smarter software, expanding access and strong product uptake position DexCom for sustained adoption and long-term growth.
Strong Preliminary Q4 Results: DexCom posted a strong preliminary fourth-quarter result, delivering double-digit revenue growth as the company continues to expand CGM access and scale its innovation pipeline. The U.S. growth has been driven by rising adoption among the rapidly expanding type 2 diabetes population, especially non-insulin and basal users, supported by deeper penetration into primary care and broader commercial reimbursement.
International momentum strengthened during the third quarter, with France and Canada emerging as key contributors following recent reimbursement gains tied to basal eligibility, while DexCom ONE+ helped bolster competitiveness in more price-sensitive European markets. This trend is likely to have continued in the fourth quarter.
Downsides
Stiff Competition: Rising competition in the Type 1 diabetes market, particularly from pump-integrated CGM systems, adds pressure. Additionally, the leadership transition in the U.S. commercial team introduces potential risks to execution as DexCom navigates these dynamics. While challenges persist, the company’s strategic initiatives and innovation-driven approach position it well for sustained growth.
DexCom has witnessed a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has moved down 1 cent to $2.46.
The consensus mark for the company’s first-quarter revenues is pegged at $1.17 billion, indicating a 12.8% improvement from the year-ago quarter’s reported number. The consensus estimate for first-quarter earnings is pinned at 48 cents per share, implying an improvement of 50% year over year.
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the loss per share estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%. You can see the complete list of today’s Zacks #1 Rankstocks here.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.3% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 67.06%.
Phibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.7% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 20.77%.
Omnicell, carrying a Zacks Rank #2 at present, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 41.7%. Revenues of $311 million beat the Zacks Consensus Estimate by 5.6%.
OMCL has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 27.9% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 38.65%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
Key Takeaways
DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. However, risks related to stiff competition persist.
This Zacks Rank #3 (Hold) company’s shares have lost 17.7% in the past six months against the industry’s 10.6% growth. The S&P 500 Index has gained 13.1% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $27.18 billion. It projects a 22.5% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed in the other two, the average surprise being 0.17%.
Let’s delve deeper.
CGM Market Represents a Huge Potential: The diabetes market offers massive long-term growth potential, with over 130 million people in the United States living with diabetes or prediabetes and more than 400 million affected globally, a figure expected to rise. This expanding patient base is driving strong demand for CGM devices, which help reduce hospitalizations, complications and overall treatment costs through real-time, user-friendly glucose tracking.
CGMs also enable more personalized diabetes management by allowing clinicians to tailor treatment plans based on individual data, while growing awareness and diagnosis of prediabetes further expand the addressable market. With the global CGM market projected to witness a 10% CAGR from over $6 billion today to about $14 billion by 2032, DexCom, as a leading CGM provider, is well positioned to deliver sustained growth over the next decade, driven by rising adoption and deeper market penetration.
Product Ecosystem and Innovation Driving Adoption: DexCom generates nearly 90% of its revenues from disposable CGM sensors, supported by strong demand driven by product performance and a positive user experience.The uptake of the G7 and One+ continues to accelerate, driven by broader insurance coverage, international expansion and growing physician support, especially among Type 2 diabetes patients.
Benefits like continuous readings without finger-pricking, comfortable wearability, and integrated alerts make DexCom’s systems compelling versus traditional glucose meters. The devices also connect to automated insulin delivery systems, which are becoming a key differentiator as diabetes care shifts toward smarter, closed-loop management.
Beyond hardware, DexCom’s software ecosystem is emerging as a powerful growth catalyst. New features, such as historical data review, AI-powered insights and deeper integration with platforms like Oura are helping patients better understand glucose trends and improve health-related decisions. This increases engagement and strengthens the company’s reimbursement case.
Stelo, launched in 2024, has already surpassed $100 million in its first year across Type 2, prediabetes and wellness markets, supported by strong subscription renewals and upcoming Amazon distribution. Together, smarter software, expanding access and strong product uptake position DexCom for sustained adoption and long-term growth.
Strong Preliminary Q4 Results: DexCom posted a strong preliminary fourth-quarter result, delivering double-digit revenue growth as the company continues to expand CGM access and scale its innovation pipeline. The U.S. growth has been driven by rising adoption among the rapidly expanding type 2 diabetes population, especially non-insulin and basal users, supported by deeper penetration into primary care and broader commercial reimbursement.
International momentum strengthened during the third quarter, with France and Canada emerging as key contributors following recent reimbursement gains tied to basal eligibility, while DexCom ONE+ helped bolster competitiveness in more price-sensitive European markets. This trend is likely to have continued in the fourth quarter.
Downsides
Stiff Competition: Rising competition in the Type 1 diabetes market, particularly from pump-integrated CGM systems, adds pressure. Additionally, the leadership transition in the U.S. commercial team introduces potential risks to execution as DexCom navigates these dynamics. While challenges persist, the company’s strategic initiatives and innovation-driven approach position it well for sustained growth.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
Estimate Trend
DexCom has witnessed a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has moved down 1 cent to $2.46.
The consensus mark for the company’s first-quarter revenues is pegged at $1.17 billion, indicating a 12.8% improvement from the year-ago quarter’s reported number. The consensus estimate for first-quarter earnings is pinned at 48 cents per share, implying an improvement of 50% year over year.
Stocks to Consider
Some better-ranked stocks from the broader medical space are AtriCure (ATRC - Free Report) , Phibro Animal Health (PAHC - Free Report) and Omnicell (OMCL - Free Report) .
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the loss per share estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%. You can see the complete list of today’s Zacks #1 Rankstocks here.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.3% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 67.06%.
Phibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.7% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 20.77%.
Omnicell, carrying a Zacks Rank #2 at present, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 41.7%. Revenues of $311 million beat the Zacks Consensus Estimate by 5.6%.
OMCL has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 27.9% rise. The company beat on earnings in each of the trailing four quarters, the average surprise being 38.65%.